Precision BioSciences shares are trading higher after the company announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD.

Precision BioSciences +4.65%

Precision BioSciences

DTIL

7.88

+4.65%

Precision BioSciences shares are trading higher after the company announced presentation of new preclinical study data supporting the potential long-term efficacy of PBGENE-DMD.